PCN95 CHANGE IN THE USE OF BREAST CONSERVING SURGERY BEFORE AND AFTER GUIDELINE PUBLICATION IN JAPAN
Fukuda H, Imanaka Y, Ishizaki T Kyoto University, Kyoto, Japan OBJECTIVE: Using 12 years of administrative data, we assessed the trends in the use of breast conserving surgery (BCS) before and after the release of clinical guidelines on BCS in Japan (published in 1999 and updated in 2005.) METHODS: We used a database from the Quality Improvement/Indicator Project that involved 40 teaching hospitals in Japan. Data on all discharged cases were collected from these hospitals from 1995. We then selected female operable breast cancer patients who were admitted to five of these hospitals from January 1996 through September 2007 (n = 1971 . A multiple regression analysis was performed to examine whether the proportion of the use of BCS after publication of guidelines was higher than that before publication, after adjusted for the effects of patient's age, comorbidity status (Charlson Comorbidity Index), hospital, and time period of admission. The Hosmer-Lemeshow test was conducted to assess the goodness-of-fit of the model. RESULTS: The proportion of BCS use increased from 16.1% in 1996 to 62.2% in 2007. Multiple logistic regression analysis revealed that patients who were <50 years old (P < 0.001) and had no comorbidity (P < 0.001) were significantly more likely to receive BCS. The proportion of BCS use has been substantially higher since 2001, two years after the BCS guidelines were published in Japan. Significant practice variations of BCS use were also confirmed among hospitals. CONCLUSION: This study confirmed the lag time between guideline publication and change in practice of BCS use. We further need to examine the potential barriers to guideline adoption related to physicians' knowledge and attitudes as well as external barriers including patient-, guideline-, and environment-related factors, to explain the reasons of change in the use of BCS over ten years.
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REAL WORLD TREATMENT PATTERNS IN HIGH RISK OR METASTATIC MELANOMA: EVIDENCE FROM THE SEER-MEDICARE LINKED DATABASE
Mitra D 1 , Davis KL 1 , Kotapati S 2 , Iloeje U 2 1 RTI Health Solutions, Research Triangle Park, NC, USA, 2 Bristol-Myers Squibb Co, Wallingford, CT, USA OBJECTIVE: To document real-world treatment patterns in elderly patients with high-risk (stage IIB/C, IIIA/B, IIIC) or metastatic (stage IV) melanoma. METHODS: Data was taken from the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database combining clinical information on incident cancer cases in the US between 1991 US between and 2002 US between with longitudinal (1991 US between -2005 Medicare claims. Subjects Ն65 years with Ն1 stage IIB or higher melanoma diagnosis and Ն6 months of subsequent benefits coverage were selected. We documented utilization patterns of four major therapies (surgery, radiation, chemotherapy, immunotherapy) following the diagnosis. RESULTS: A total of 6470 subjects met all criteria. Stage distribution was: IIB/C (38%); IIIA/B (46%); IIIC (1%); IV (15%). Median follow-up was 56, 39, 16, and 6 months, respectively. Surgery (primarily tumor excision) was the predominant 1st line treatment, received by >85% of subjects with stage IIB/C, IIIA/B, or IIIC melanoma and 60% of stage IV cases, but was a rare 2nd line approach. Radiation was 1st line treatment in only 2%, 5%, and 13% of stage IIB/C, IIIA/B, and IIIC cases, respectively, but was more common as a 2nd line approach in these subjects (15%, 24%, and 41%, respectively). Radiation was equally prevalent (~30% of cases) as 1st or 2nd line treatment in stage IV. Chemotherapy was uncommon as 1st line treatment (<4% of all cases), but prevalent as 2nd line therapy (by respective stage, 14%, 20%, 41%, and 22% of cases). Immunotherapy was rare, except as 2nd line treatment in stage IIIC (26% of cases). CON-CLUSION: Beyond surgery as a 1st line approach, relatively few patients received other types of treatment as either 1st or 2nd line therapy. These findings demonstrate an unmet need in high risk and metastatic melanoma. Additional analyses of administrative data characterizing real-world treatment patterns in melanoma are needed to help inform the direction of future clinical trials.
GASTROINTESTINAL DISORDERS-Clinical Outcomes Studies
PGI1 HETEROGENEITY ACROSS RANDOMIZED CONTROLLED TRIALS OF PROTON-PUMP INHIBITORS IN NIGHTTIME GERD: A SYSTEMATIC REVIEW
Kothawala P 1 , Lange SM 2 , McGuigan JE 3 , Aguilar D 1 , Morgenstern D 4 , Yan N 4 , Dean BB 1 1 Cerner LifeSciences, Beverly Hills, CA, USA, 2 Mayo Clinic Jacksonville, Jacksonville, FL, USA, 3 University of Florida, Gainesville, FL, USA, 4 Wyeth Pharmaceuticals, Collegeville, PA, USA OBJECTIVE: Numerous randomized controlled trials (RCTs) have evaluated efficacy of proton-pump inhibitors (PPIs) in controlling nighttime symptoms of gastroesophageal reflux disease (GERD). Quantitative synthesis of the effect of PPIs on nighttime symptoms is lacking, thus the validity of performing a metaanalysis was assessed. METHODS: MEDLINE and EMBASE Abstracts A83 databases from 1990-June 2007 were systematically searched for RCTs evaluating the efficacy of PPIs on nighttime symptoms in adults with GERD. Methodological and clinical homogeneity across studies was explored. Methodological diversity or differences in study quality evaluated by Jadad score (ranging from 1 = low to 5 = high) and clinical diversity in nighttime criteria used for patient enrollment, nighttime outcomes measured, and the nighttime definition used were explored. RESULTS: Thirtytwo RCTs compared the efficacy of PPI with placebo only (n = 7), H2-receptor antagonist only (n = 12), another PPI only (n = 11) or both placebo and H2-receptor antagonist (n = 2) in controlling nighttime GERD. The majority of studies (n = 28) were of high methodological quality (Jadad score of at least 3 points). Source of data collection was patient daily diaries across all studies. Criteria for enrolling nighttime GERD patients (frequency and/or severity of nighttime symptoms) lacked consistency. Nighttime heartburn measures varied from percentage of patients without heartburn (n = 18), percentage of heartburnfree nights (n = 15), heartburn severity score (n = 11) or time to heartburn relief (n = 6). Most studies assessed efficacy at eight weeks or less; only three studies measured the long-term efficacy of PPI. However, very few nighttime heartburn measures assessed the same timeframe. The time window for the nighttime symptom assessment was reported in only three studies and was not based on specific hours but on sleep/posture (retiring/lying down to sleep). CONCLUSION: RCTs of PPI therapy in nighttime GERD are of high methodological quality. However, presence of clinical heterogeneity across trials in enrollment criteria, outcomes, and timeframes minimizes the possibility of performing meta-analysis. year follow-up which ended at first hospitalization for serious GI event (the outcome), the last dispensing, or the end of the study period. Chronic users were defined as patients who used any NSAIDs for Ն60 days during the first year of follow-up (n = 58770); other NSAID users were acute users (n = 538.420). Multivariate analysis by Poisson regression adjusted for sex, age, duration of follow-up, tNSAID and coxib dose, adherence to NSAIDs or PPIs, gastroprotection, anticoagulants, acetaminophen, corticosteroids, and cardiovascular disease. RESULTS: The cohort included 52,953 new tNSAIDs+PPI users and 80,756 new Coxib users, with main characteristics: mean (ϮSD) age 58.1 Ϯ 15.5 vs. 56.7 Ϯ 17.5; female 55.3% vs. 62.2%; mean duration of treatment (days): 137 Ϯ 217 vs. 138 Ϯ 179, respectively. Among acute users, adjusted hazard ratios (95% Confi-dence Interval) of hospitalizations were 0.21 (0.14-0.32) for upper and 0.26 (0.16-0.42) for lower GI events, for Coxib versus tNSAIDs+PPI users. Among chronic users, adjusted hazard ratios were 0.35 (0.22-0.55) for upper GI and 0.43 (0.25-0.75) for lower GI events, for Coxib versus tNSAIDs+PPI users. CON-CLUSION: Acute and chronic Coxib users had a statistically significantly lower rate of hospitalizations for upper and lower GI events compared to tNSAIDS+PPI users. Future research is needed to explain these findings, possibly due to prescribing for non-preventive reasons.
PGI2 HOSPITALIZATIONS FOR GASTROINTESTINAL EVENTS AMONG USERS OF COX 2 INHIBITORS COMPARED WITH TRADITIONAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS WITH PROTON-PUMP INHIBITORS
GASTROINTESTINAL DISORDERS-Cost Studies
PGI3 COST OF PATIENT CARE IN PATIENTS WITH ULCERATIVE COLITIS IN BRAZIL: PUBLIC HEALTH PERSPECTIVE
Araujo G, Fonseca M Axia.Bio Consulting, São Paulo, Brazil OBJECTIVE: Ulcerative colitis (UC) is a chronic condition that afflicts young adults in their economically productive years. Because of its long duration, UC causes high use of health services and high lifetime costs for medical care. The aim of this study was to measure the annual costs of patients with UC from the Brazilian public heath perspective and to identify potentially relevant determinants of costs. METHODS: Thirty-one gastroenterologists from southeast Brazil prospectively evaluated all their UC patients during two months. They used a structured questionnaire specifically developed to evaluate resource use by patients with ulcerative colitis. Costs of medical services (diagnostics and treatment) were considered as well as costs of medication. Resource use was valued using government reimbursement for hospital services and government tender prices drugs. RESULTS: A total of 175 patients were evaluated. The mean annual cost of one CD patient was R$1945.06, including medication, physician, laboratory, diagnostic, hospitalization and surgery costs. Medication, hospitalization, surgery and diagnostic procedures accounted respectively for 95%, 3%, 1%, and 1% of the total annual costs. Mesalazine was the most used drug to initiate UC′s treatment (58%). There was no statistical difference between the costs of the patients treated with mesalazine and sulfasalazine. Due to differences in the mean dosage of theses drugs, mesalazine daily cost is lower than sulfasalazine. CON-CLUSION: This is the first time that UC treatment costs have been demonstrated from the Brazilian public health perspective. Although mesalazine is deemed to be more expensive than sulfasalazine and considering that there was no statistical difference in total costs among patients taking mesalazine and sulfasalazine, and that medications represent more than 90% of total UC treatment annual costs in the public Brazilian health care system, the use of mesalazine may represent a reduction factor in the financial resource expenditure for the treatment of UC.
PGI4 A BRAZILIAN CROSS SECTIONAL STUDY TO EVALUATE HOSPITALIZATION AMONG MODERATE AND SEVERE CROHNЈS DISEASE PATIENTS
Araujo G, Fonseca M Axia.Bio Consulting, São Paulo, Brazil OBJECTIVE: Infliximab improves patient quality of life and is effective to control Crohn's disease refractory to the standard treatment. It lacks real world Brazilian data demonstrating that this improvement in quality of life and disease control is related to decrease of resource use mainly due to hospitalization reduction in moderate and severe Crohn disease patients receiving
